Johnson & Johnson (JNJ): What This Company Actually Does

How JNJ makes money

Johnson & Johnson operates two engines: Innovative Medicine, which develops prescription drugs for cancer, immunology, and neurological conditions, and MedTech, which makes hospital devices for cardiology, orthopedics, surgery, and vision. Both engines feed off heavy R&D reinvestment (15.6% of revenue), and products reach patients through wholesalers and hospitals, with health insurers and government programs (like Medicare) ultimately paying the bill — not the patient directly.

Source: 10-K FY2025, p.1 (segment structure), p.23-24, 27 (2025 segment revenue), p.89 (wholesaler concentration), p.44 (R&D expense).

Where the revenue comes from

2025 pretax margin: Innovative Medicine 36.9%, MedTech 12.2%.

Source: 10-K FY2025, p.89 (Note 17, segment revenue and profit).

Geographically (2025, total $94.2B): the U.S. is 57.1%, Europe 22.9%, Western Hemisphere ex-U.S. 5.2%, and Asia-Pacific/Africa 14.9%. With 43% of revenue coming from outside the U.S., JNJ is exposed to currency risk when the dollar strengthens, as well as geopolitical risk from drug-pricing cuts and tariff policy abroad.

Source: 10-K FY2025, p.89 (Note 17, revenue by geography).

Customers and competitors

A strictly B2B structure — JNJ doesn't sell directly to patients. Products flow through wholesalers to hospitals, pharmacies, and doctors, with health insurers and governments (like U.S. Medicare) ultimately reimbursing the cost.

• AbbVie — a direct rival in immunology; AbbVie's Skyrizi and Rinvoq are rapidly taking share from JNJ's Stelara and Tremfya.
• Merck & Co. — the dominant force in oncology through Keytruda, competing against JNJ's Darzalex and Carvykti.
• Medtronic — a pure medical-device competitor with no drug business, competing with JNJ MedTech in cardiac and surgical devices; without a drug portfolio, Medtronic doesn't face JNJ's patent-cliff exposure.

Source: 10-K FY2025, p.89 (wholesaler concentration).

The metric that matters most in this sector

A patented drug is highly profitable only while its patent lasts. Once it expires ("loss of exclusivity"), biosimilar competitors flood in and revenue can collapse quickly. JNJ's #2 product, Stelara, is living through exactly this process right now — a preview of what awaits Darzalex (15% of revenue, U.S. patent expires 2029) and Tremfya (2031).

Source: earnings call transcripts, Q1-Q4 FY2025, Q1-Q2 FY2026 (roic.ai); U.S. revenue figures, 10-K FY2025, p.24.

Leadership and ownership

CEO Joaquin Duato has served as Chairman and CEO since 2022 — an internal promotion from Worldwide Chairman of the pharmaceutical business, with more than 30 years at the company. There's no founder involvement — JNJ was founded in 1886, and the founding family plays no role in current management. Combined insider ownership is under 1%. The largest shareholders are institutional managers BlackRock (about 7.7%, 186.3M shares) and State Street (about 5.5%, 133.0M shares).

Source: DEF 14A 2026, p.2 (executive/director ownership table, 5%+ shareholder disclosure — BlackRock/State Street figures reflect a January 2024 Schedule 13G filing, somewhat dated).

Capital returns

JNJ raised its dividend for the 63rd consecutive year through 2025 — a Dividend King. It paid $5.14/share in 2025, with a quarterly dividend of $1.30/share ($5.20 annualized) payable in March 2026, yielding about 1.96% at the current price.

Source: 10-K FY2025, p.35 (dividend), p.44, 46-47 (buybacks and share count).

How this company could fail

• Patent cliff / biosimilar erosion — Darzalex (15% of revenue, U.S. patent expires 2029) and Tremfya (5.5%, expires 2031) will eventually follow the path Stelara (6.5% of revenue, currently down 55.7% quarterly) is walking now. These three major drugs together account for 27% of revenue.
• Talc (baby powder) litigation — tens of thousands of cancer-related lawsuits remain active; two bankruptcy filings were both rejected by courts, and a 2025 Texas lawsuit was also dismissed, sending the matter back to ordinary civil litigation. Reversing about $7.0 billion in prior reserves boosted 2025 profit significantly, but $3.4 billion in reserves remain, and final settlement costs could exceed that.
• Wholesaler concentration plus rising debt — three wholesalers account for 48% of revenue, and debt jumped from $36.6B to $47.9B in 2025 to fund acquisitions (including Intra-Cellular Therapeutics for $14.5B). Still manageable (net debt/EBITDA around 0.85x), but continued acquisition pace could tighten financial flexibility.

Source: 10-K FY2025, p.65, 86; 10-K FY2022, p.73, 85 (opioid litigation reserve context).

Five-year financials

*Operating income = gross profit minus SG&A, R&D, IPR&D impairment, and restructuring costs (a self-calculated figure excluding interest, other income/expense, and litigation — see footnotes). **FCF = operating cash flow minus capex. Source: 10-K FY2025 p.44, 46-47, 89 (2023-2025); 10-K FY2023 p.45, 47-48 (2021-2022); 2021 total debt not confirmable from available filings.

What we still don't know

• The specific structure and timeline of the planned Orthopaedics spinoff — announced in October 2025 as a review targeting completion within 18-24 months, but whether it will be a Kenvue-style spinoff or a sale, and at what valuation, isn't disclosed.
• The final talc litigation settlement amount and when it will conclude — $3.4 billion in reserves remain and several court rulings are expected in 1H 2026, but the ultimate additional cost depends on litigation outcomes that can't be predicted here.
• How quickly Darzalex and Tremfya will actually erode after losing patent protection — Stelara's erosion rate is now well documented, but each drug's underlying patent strength and pipeline-replacement dynamics differ, so the same pace can't be assumed.